Neuron-specific block of T-type calcium channels
T 型钙通道的神经元特异性阻断
基本信息
- 批准号:8117447
- 负责人:
- 金额:$ 19.85万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2011
- 资助国家:美国
- 起止时间:2011-03-15 至 2013-02-28
- 项目状态:已结题
- 来源:
- 关键词:AddressAdverse effectsAfferent NeuronsAmericanAnalgesicsAnimal ModelAnimalsAntisense OligonucleotidesBiological AssayCalcium ChannelCapsidCapsid ProteinsCell LineCell NucleusChronicClinicalClinical TrialsDNA deliveryDevelopmentDiabetic NeuropathiesDirect CostsDoxycyclineElementsFacilities and Administrative CostsFundingFutureGene TransferGenesGoalsGrantHealthHumanHyperalgesiaIn VitroIntrathecal InjectionsIon ChannelKnockout MiceMagicMeasuresMechanicsMediatingMedicalMessenger RNAModelingMusNeuronsNociceptionNociceptorsPainPatientsPharmaceutical PreparationsPhysiologyProductionProductivityQuality of lifeRattusRecombinant adeno-associated virus (rAAV)RegulationResearchReverse Transcriptase Polymerase Chain ReactionRodentRoleSerotypingSignal TransductionSliceSmall Interfering RNASodium ChannelSpinal GangliaStaining methodStainsT-Type Calcium ChannelsTestingTetanus Helper PeptideTetracyclinesThioctic AcidUnited StatesValidationViralallodyniabasechronic painclinically relevantcostdesigndiabetic ratdrug developmentganglion cellgene therapyhuman ZNF45 proteinhuman tissuein vivoinnovationnerve injurynovelpain inhibitionpainful neuropathyparticlepromoterselective expressionsmall hairpin RNAtooltransmission processvectorvoltage
项目摘要
DESCRIPTION (provided by applicant): Pain is a leading health problem in the United States with 1 in 10 Americans suffering from moderate to severe pain. Yet, the treatment of chronic pain remains a clinical challenge, with only half of patients receiving adequate pain relief. Therefore, the development of novel analgesics without abuse potential and side effects would have significant impact on the treatment of pain. The hypothesis guiding these exploratory studies is that chronic pain can be treated by inhibiting ion channels in nociceptors such as the Cav3.2 T-type voltage-gated calcium channel. T-currents are upregulated in animal models of chronic constrictive nerve injury and diabetic neuropathy, and Cav3.2 directed antisense oligonucleotides reverse the mechanical hyperalgesia and allodynia observed in these animals. Importantly, Cav3.2 is important for pain signaling in both rodents and humans, since the clinically relevant analgesic, lipoic acid, blocks human Cav3.2 currents in vitro yet is ineffective in Cav3.2 knockout mice in vivo. These studies will develop short hairpin RNAs (shRNA) that inhibit the expression of mouse and human Cav3.2 channels. In contrast to chemically synthesized siRNA, delivery of DNA-based shRNA can be specifically targeted to neuronal subtypes using gene promoters. The present study will explore the use of the sodium channel promoter Scn10a, whose expression is largely limited to nociceptors. An important feature for clinical use is the ability to regulate gene therapy. This will be accomplished using a newly developed version of the tetracycline repressor, which requires drug for activation (doxycycline-ON). Recombinant adeno-associated virus (rAAV) has emerged as the top choice for human gene therapy. AAV particles can be produced with protein coats that effectively infect sensory neurons and are retrogradely transported to the nucleus (e.g. serotype 8). The goal of these studies is to develop rAAV targeting vectors that direct shRNA- mediated knockdown of Cav3.2, use this to prepare viral particles, and then test for nociceptor- specific expression in rats with neuropathic pain. The research team includes Dr. Edward Perez- Reyes, a T-channel expert, Dr. Guanping Gao, an AAV expert, and Dr. Hui-Lin Pan, a neuropathic pain expert.
PUBLIC HEALTH RELEVANCE: Project Narrative Chronic pain affects over 10% of the population, resulting in lowered productivity and quality of life. The present proposal is focused on developing a novel treatments of pain that can provide long-term treatment without abuse potential.
Disclaimer: Please note that the following critiques were prepared by the reviewers prior to the Study Section meeting and are provided in an essentially unedited form. While there is opportunity for the reviewers to update or revise their written evaluation, based upon the group's discussion, there is no guarantee that individual critiques have been updated subsequent to the discussion at the meeting. Therefore, the critiques may not fully reflect the final opinions of the individual reviewers at the close of group discussion or the final majority opinion of the group. Thus the Resume and Summary of Discussion is the final word on what the reviewers actually considered critical at the meeting.
描述(由申请人提供):疼痛是美国的主要健康问题,十分之一的美国人患有中度至重度疼痛。然而,慢性疼痛的治疗仍然是一个临床挑战,只有一半的患者得到充分的疼痛缓解。因此,开发无滥用潜力和副作用的新型镇痛药将对疼痛治疗产生重大影响。指导这些探索性研究的假设是,慢性疼痛可以通过抑制伤害感受器中的离子通道如Cav3.2 T型电压门控钙通道来治疗。 在慢性缩窄性神经损伤和糖尿病性神经病变的动物模型中,T电流上调,并且Cav3.2定向的反义寡核苷酸逆转在这些动物中观察到的机械性痛觉过敏和异常性疼痛。 重要的是,Cav3.2对于啮齿类动物和人类的疼痛信号传导都很重要,因为临床相关的镇痛剂硫辛酸在体外阻断人Cav3.2电流,但在体内Cav3.2敲除小鼠中无效。这些研究将开发短发夹RNA(shRNA),抑制小鼠和人类Cav3.2通道的表达。与化学合成的siRNA相反,基于DNA的shRNA的递送可以使用基因启动子特异性靶向神经元亚型。本研究将探讨使用钠通道启动子Scn 10a,其表达主要限于伤害感受器。临床应用的一个重要特征是调节基因治疗的能力。这将使用新开发的四环素阻遏物版本来完成,其需要药物来激活(强力霉素-ON)。重组腺相关病毒(rAAV)已成为人类基因治疗的首选。AAV颗粒可以产生具有蛋白质外壳的,其有效地感染感觉神经元并被逆行转运到细胞核(例如血清型8)。这些研究的目标是开发指导shRNA介导的Cav3.2敲低的rAAV靶向载体,用其制备病毒颗粒,然后在患有神经性疼痛的大鼠中测试伤害感受器特异性表达.该研究团队包括T通道专家Edward Perez- Reyes博士,AAV专家Guanping Gao博士和神经性疼痛专家Hui-Lin Pan博士。
慢性疼痛影响超过10%的人口,导致生产力和生活质量下降。目前的建议集中在开发一种新的疼痛治疗方法,可以提供长期治疗而没有滥用的可能性。
免责声明:请注意,以下评论由审查员在研究部分会议之前准备,并以基本上未经编辑的形式提供。 虽然审查人员有机会根据小组讨论情况更新或修订其书面评价,但不能保证在会议讨论之后更新了个人评论。 因此,这些评论可能并不完全反映小组讨论结束时单个评审员的最终意见或小组的最终多数意见。因此,讨论的简历和摘要是评审员在会议上实际认为关键的最后一句话。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
EDWARD PEREZ-REYES其他文献
EDWARD PEREZ-REYES的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('EDWARD PEREZ-REYES', 18)}}的其他基金
Validation of a novel mouse model of temporal lobe epilepsy
新型颞叶癫痫小鼠模型的验证
- 批准号:
9810436 - 财政年份:2019
- 资助金额:
$ 19.85万 - 项目类别:
Validation of a Novel Mouse Model of Temporal Lobe Epilepsy
颞叶癫痫新型小鼠模型的验证
- 批准号:
10618726 - 财政年份:2019
- 资助金额:
$ 19.85万 - 项目类别:
Developing a drug-inducible gene therapy for temporal lobe epilepsy
开发药物诱导的颞叶癫痫基因疗法
- 批准号:
10800000 - 财政年份:2016
- 资助金额:
$ 19.85万 - 项目类别:
Developing a drug-inducible gene therapy for temporal lobe epilepsy
开发药物诱导的颞叶癫痫基因疗法
- 批准号:
9156597 - 财政年份:2016
- 资助金额:
$ 19.85万 - 项目类别:
Probing epileptic circuits with novel Cre- and drug-regulated genetic approaches
用新型 Cre 和药物调节的遗传方法探索癫痫回路
- 批准号:
8913446 - 财政年份:2015
- 资助金额:
$ 19.85万 - 项目类别:
Neuron-specific block of T-type calcium channels
T 型钙通道的神经元特异性阻断
- 批准号:
8235787 - 财政年份:2011
- 资助金额:
$ 19.85万 - 项目类别:
Mechanisms by which T-type calcium channels increase seizure susceptibility
T型钙通道增加癫痫易感性的机制
- 批准号:
7776541 - 财政年份:2009
- 资助金额:
$ 19.85万 - 项目类别:
Development of High Throughput Assays for HVA CA Channels
HVA CA 通道高通量检测的开发
- 批准号:
7049771 - 财政年份:2006
- 资助金额:
$ 19.85万 - 项目类别:
Development of High Throughput Assays for N-type Calcium Channels
N 型钙通道高通量检测的开发
- 批准号:
7345651 - 财政年份:2006
- 资助金额:
$ 19.85万 - 项目类别:
MOLECULAR ANALYSIS OF NEURONAL T TYPE CA++ CHANNELS
神经元 T 型 CA 通道的分子分析
- 批准号:
6540099 - 财政年份:1999
- 资助金额:
$ 19.85万 - 项目类别:
相似海外基金
Unraveling Adverse Effects of Checkpoint Inhibitors Using iPSC-derived Cardiac Organoids
使用 iPSC 衍生的心脏类器官揭示检查点抑制剂的副作用
- 批准号:
10591918 - 财政年份:2023
- 资助金额:
$ 19.85万 - 项目类别:
Optimization of mRNA-LNP vaccine for attenuating adverse effects and analysis of mechanism behind adverse effects
mRNA-LNP疫苗减轻不良反应的优化及不良反应机制分析
- 批准号:
23K15383 - 财政年份:2023
- 资助金额:
$ 19.85万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Elucidation of adverse effects of combined exposure to low-dose chemicals in the living environment on allergic diseases and attempts to reduce allergy
阐明生活环境中低剂量化学品联合暴露对过敏性疾病的不良影响并尝试减少过敏
- 批准号:
23H03556 - 财政年份:2023
- 资助金额:
$ 19.85万 - 项目类别:
Grant-in-Aid for Scientific Research (B)
Green tea-based nano-enhancer as an adjuvant for amplified efficacy and reduced adverse effects in anti-angiogenic drug treatments
基于绿茶的纳米增强剂作为抗血管生成药物治疗中增强疗效并减少不良反应的佐剂
- 批准号:
23K17212 - 财政年份:2023
- 资助金额:
$ 19.85万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Effects of Tobacco Heating System on the male reproductive function and towards to the reduce of the adverse effects.
烟草加热系统对男性生殖功能的影响以及减少不利影响。
- 批准号:
22H03519 - 财政年份:2022
- 资助金额:
$ 19.85万 - 项目类别:
Grant-in-Aid for Scientific Research (B)
Mitigating the Adverse Effects of Ultrafines in Pressure Filtration of Oil Sands Tailings
减轻油砂尾矿压力过滤中超细粉的不利影响
- 批准号:
563657-2021 - 财政年份:2022
- 资助金额:
$ 19.85万 - 项目类别:
Alliance Grants
1/4-Deciphering Mechanisms of ECT Outcomes and Adverse Effects (DECODE)
1/4-破译ECT结果和不良反应的机制(DECODE)
- 批准号:
10521849 - 财政年份:2022
- 资助金额:
$ 19.85万 - 项目类别:
4/4-Deciphering Mechanisms of ECT Outcomes and Adverse Effects (DECODE)
4/4-破译ECT结果和不良反应的机制(DECODE)
- 批准号:
10671022 - 财政年份:2022
- 资助金额:
$ 19.85万 - 项目类别:
2/4 Deciphering Mechanisms of ECT Outcomes and Adverse Effects (DECODE)
2/4 ECT 结果和不良反应的破译机制(DECODE)
- 批准号:
10670918 - 财政年份:2022
- 资助金额:
$ 19.85万 - 项目类别:
Downsides of downhill: The adverse effects of head vibration associated with downhill mountain biking on visuomotor and cognitive function
速降的缺点:与速降山地自行车相关的头部振动对视觉运动和认知功能的不利影响
- 批准号:
2706416 - 财政年份:2022
- 资助金额:
$ 19.85万 - 项目类别:
Studentship